2. Wang Y, Zhou S, Yang F, et al. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. JAMA Oncol. 2019, 5(7): 1008-1019. doi: 10.1001/jamaoncol.2019.0393....
6、Yucai Wang, Shouhao Zhou, Fang Yang, et al. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis[J]. JAMA Oncol. 2019 Jul 1;5(7):1008-1019. 7、Rathi N Pillai, Madhusmita Behera, ...
[17]FENG Z, RONG P, WANG W. Meta-analysis of the efficacy and safety of PD-1/PD-L1 inhibitors administered alone or in combination with anti-VEGF agents in advanced hepatocellular carcinoma[J]. Gut, 2020, 69(10): 1904-1906. DOI: 10.1136/gutjnl-2019-320116 [18]KUDO M. Immuno-oncol...
Bao KKH, Wong ICK, Tse G, Zhang Q. Adverse Cardiovascular Complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched Cohort Study with competing risk analysis. Cardiooncology. 2022 Mar 17;8(1):5. ...
WoodsDM, SodréAL, VillagraA, et al.HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade[J]．Cancer Immunol Res, 2015, 3(12): 1375-1385.DOI: 10.1158/2326-6066.Cir-15-0077-t.HoggSJ, VervoortSJ, DeswalS, et al.BET-bromodomain inhibitors ...
谁将会率先获得积极数据，成为首个上市的黑马？让我们拭目以待。参考资料：1. Insight 数据库；2. Progress in the application of PD-1 /PD-L1 inhibitors in neoadjuvant chemotherapy，Chinese Journal of New Drugs，2020；3. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer．New Eng J Med， 2018.
[4] Wu Q, Jiang L, Li SC, et al. Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway. Acta Pharmacol Sin. 2021, 42(1): 1-9. doi: 10.1038/s41401-020-0366-x. [5] Lin KX, Istl AC, Quan D, et al. PD-1 and PD-L1 inhibitors in cold colorectal cancer: chal...
[3]. Abdin SM, et al. Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors. Cancers (Basel). 2018 Jan 25;10(2):32. [4]. Chen X, et al. FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer ...
1.D. B. Doroshow et al., PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol 18, 345-362 (2021).2. R. S. Finn et al., Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 382, 1894-1905 (2020).3. L. Paz-Ares et...
4.Wu, Q., Jiang, L., Li, Sc. et al. Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway. Acta Pharmacol Sin 42, 1–9 (2021). 5.Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B, et al. Structure of the complex of human programmed death 1, ...